综上，近年来，随着PAD患者人数的增加，CLI患者人数也逐年递增。然而，CLI的治疗主要依赖于外科治疗，旨在通过绕过或消除动脉阻塞来重建血运，实现CLI的治疗目的。并且，并非所有的CLI患者适用于外科手术治疗来重建血运，针对这部分患者只能采用药物保守治疗和截肢，或面临死亡。CLI的治疗尚无完全治愈的药物，临床亟需针对CLI新疗法的开发，未来CLI的药物市场潜力巨大。

参考文献：

[1] 陈跃鑫, 周梦馨, 刘昌伟. 下肢缺血性疾病规范化治疗争议与共识[J]. 中国实用外科杂志,2017, 037(012):1349-1354.

[2] 中华医学会医学工程学分会肝细胞工程专业委员会. 自体干细胞移植规范化治疗下肢慢性缺血性疾病的专家共识[J]. 中华细胞与干细胞杂志:电子版, 2012(01):7-10.

[3] Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG. In-ter-Society Consensus for the Management of Peripheral Arterial Disease(TASC II). J Vasc Surg 2007;45 Suppl S:S5-67.

[4] Fowkes FGR, Rudan D, Rudan I, Aboyans V, Denenberg JO, McDermottMM, et al. Comparison of global estimates of prevalence and risk factors forperipheral ar-tery disease in 2000 and 2010: a system-atic review and analysis. Lancet. 2013;382:1329-40. Med-line: doi:10.1016/S0140-6736(13)-0

[5] Peige, Song, Diana, et al. National and subnational estimation ofthe prevalence of pe-ripheral artery disease (PAD) in China: a systematic review and meta-analysis[J]. Journal of Global Health, 2019.

[6] Wang Z , Wang X , Hao G , et al. A national study of the prevalence and risk factors associated with peripheral arterial disease from China: The China Hypertension Survey, 2012–2015[J]. Int J Cardiol, 2019, 275:165-170.

[7] 沙利文公开报告：主动脉及周围血管介入器械行业独立市场研究

[8] Baocheng X, Houlong L, Yusheng Z, et al. Autologous Stem Cell Therapy in Criti-cal Limb Ischemia: A Meta-Analysis of Randomized Controlled Trials[J]. Stem Cells In-terna-tional, 2018, 2018:1-12.

[10] Nehler MR, Duval S, Diao LH, et al. Epidemiology of peripheralarte-rial disease and critical limb ischemia in an insured nationalpopulation[J]. J Vasc Surg, 2014, 60(3): 686-695.

[12] 德国血管学协会. 周围动脉疾病诊断和治疗指南. 2011

[13] Alik Farber, Robert T. Eberhardt. The Current State of Critical Limb Ischemia: A Systematic Review[J]. JAMA Surgery, 2016, 151(11):1070.

[14] Lawall H, Bramlage P, Amann B. Treatment of peripheralarterial disease using stem and progenitor cell therapy[J]. Journal of VascularSurgery, 2011, 53(2):0-453.

[15] Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG. In-ter-Society Consensus for the Management of Peripheral Arterial Disease(TASC II). J Vasc Surg 2007;45 Suppl S:S5-67.

[17] Zhihui D, Tianyue P, Yuan F, et al. Purified CD34+ cells versus peripheral blood mononuclear cells in the treatment of angiitis-induced no-option criticallimb ischae-mia: 12-Month results of a prospective ran-domised single-blinded non-inferiority tri-al[J]. EBioMedicine, 2018:SX-.?[18]

文章来源：《中国实用医药》 网址: http://www.zgsyyyzzs.cn/zonghexinwen/2020/0713/385.html